(OSCR) Oscar Health - Overview
Sector: Healthcare | Industry: Healthcare Plans | Exchange: NYSE (USA) | Market Cap: 6.702m USD | Total Return: 55.9% in 12m
Avg Turnover: 177M
Qual. Beats: 1
Rev. Trend: 99.4%
Qual. Beats: -3
Warnings
Choppy
Tailwinds
Supp Ema20, Rs Leader, Idiosyncratic Leader, Confidence
Oscar Health, Inc. (OSCR) is a technology-driven healthcare company providing health insurance plans to individuals, families, and small business groups across the United States. The firm distinguishes itself through its proprietary full-stack technology platform, +Oscar, which facilitates member engagement, provider recommendations, and administrative efficiency for internal operations and third-party payors.
Operating within the Life & Health Insurance sector, the company utilizes a digital-first business model to manage medical loss ratios and streamline the enrollment process for brokers and consumers. Unlike traditional insurers that often rely on legacy infrastructure, Oscar Health integrates reinsurance products and brokerage services into its ecosystem to diversify revenue streams. Investors can further analyze these operational metrics and valuation trends on ValueRay.
The company, headquartered in New York, underwent a corporate rebranding from Mulberry Health Inc. in 2021. Its current service suite includes the Campaign Builder platform, designed to optimize healthcare outcomes through data-driven member interventions.
- Medical Loss Ratio improvements drive path toward sustainable GAAP net profitability
- Individual Exchange enrollment growth fuels core health insurance premium revenue expansion
- Scaling +Oscar technology platform diversifies revenue via high-margin SaaS third-party contracts
- Federal subsidy shifts and ACA regulatory changes impact market share stability
- Expansion into the small group market provides critical membership diversification beyond individuals
| Net Income: -39.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.30 > 0.02 and ΔFCF/TA 9.74 > 1.0 |
| NWC/Revenue: 4.79% < 20% (prev -3.71%; Δ 8.50% < -1%) |
| CFO/TA 0.31 > 3% & CFO 2.84b > Net Income -39.4m |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (329.8m) vs 12m ago 7.78% < -2% |
| Gross Margin: 17.39% > 18% (prev 0.57%; Δ 1.68k% > 0.5%) |
| Asset Turnover: 175.8% > 50% (prev 172.5%; Δ 3.28% > 0%) |
| Interest Coverage Ratio: -0.59 > 6 (EBITDA TTM 19.2m / Interest Expense TTM 17.0m) |
| A: 0.07 (Total Current Assets 7.78b - Total Current Liabilities 7.14b) / Total Assets 9.29b |
| B: -0.28 (Retained Earnings -2.62b / Total Assets 9.29b) |
| C: -0.00 (EBIT TTM -9.95m / Avg Total Assets 7.57b) |
| D: -0.34 (Book Value of Equity -2.61b / Total Liabilities 7.62b) |
| Altman-Z'' = -0.84 = CCC |
| DSRI: 0.58 (Receivables 587.0m/763.4m, Revenue 13.3b/10.1b) |
| GMI: 3.28 (GM 17.39% / 57.10%) |
| AQI: 0.45 (AQ_t 0.15 / AQ_t-1 0.34) |
| SGI: 1.32 (Revenue 13.3b / 10.1b) |
| TATA: -0.31 (NI -39.4m - CFO 2.84b) / TA 9.29b) |
| Beneish M = -1.72 (Cap -4..+1) = CCC |
As of June 01, 2026, the stock is trading at USD 22.23 with a total of 4,165,903 shares traded.
Over the past week, the price has changed by +0.41%,
over one month by +20.42%,
over three months by +59.01% and
over the past year by +55.89%.
Oscar Health has received a consensus analysts rating of 3.29. Therefore, it is recommended to hold OSCR.
- StrongBuy: 2
- Buy: 1
- Hold: 2
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 21.2 | -4.6% |
P/E Forward = 588.2353
P/S = 0.5038
P/B = 4.0279
Revenue TTM = 13.3b USD
EBIT TTM = -9.95m USD
EBITDA TTM = 19.2m USD
Long Term Debt = 430.9m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 430.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -6.37b USD (calculated: Debt 430.9m - CCE 6.80b)
Enterprise Value = 333.3m USD (6.70b + Debt 430.9m - CCE 6.80b)
Interest Coverage Ratio = -0.59 (Ebit TTM -9.95m / Interest Expense TTM 17.0m)
EV/FCF = 0.12x (Enterprise Value 333.3m / FCF TTM 2.80b)
FCF Yield = 839.9% (FCF TTM 2.80b / Enterprise Value 333.3m)
FCF Margin = 21.04% (FCF TTM 2.80b / Revenue TTM 13.3b)
Net Margin = -0.30% (Net Income TTM -39.4m / Revenue TTM 13.3b)
Gross Margin = 17.39% ((Revenue TTM 13.3b - Cost of Revenue TTM 11.0b) / Revenue TTM)
Gross Margin QoQ = 30.50% (prev 6.60%)
Tobins Q-Ratio = 0.04 (Enterprise Value 333.3m / Total Assets 9.29b)
Interest Expense / Debt = 3.94% (Interest Expense 17.0m / Debt 430.9m)
Taxrate = 2.83% (19.8m / 698.8m)
NOPAT = -9.67m (EBIT -9.95m * (1 - 2.83%)) [loss with tax shield]
Current Ratio = 1.09 (Total Current Assets 7.78b / Total Current Liabilities 7.14b)
Debt / Equity = 0.26 (Debt 430.9m / totalStockholderEquity, last quarter 1.66b)
Debt / EBITDA = -331.2 (out of range, set to none) (Net Debt -6.37b / EBITDA 19.2m)
Debt / FCF = -2.28 (Net Debt -6.37b / FCF TTM 2.80b)
Total Stockholder Equity = 1.21b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.52% (Net Income -39.4m / Total Assets 9.29b)
RoE = -1.03% (Net Income TTM -39.4m / Total Stockholder Equity 3.82b)
RoCE = -0.23% (EBIT -9.95m / Capital Employed (Equity 3.82b + L.T.Debt 430.9m))
RoIC = -0.45% (negative operating profit) (NOPAT -9.67m / Invested Capital 2.13b)
WACC = 9.82% (E(6.70b)/V(7.13b) * Re(10.20%) + D(430.9m)/V(7.13b) * Rd(3.94%) * (1-Tc(0.03)))
Discount Rate = 10.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 33.33 | Cagr: 18.03%
[DCF] Terminal Value 73.38% ; FCFF base≈2.16b ; Y1≈2.47b ; Y5≈3.64b
[DCF] Fair Price = 187.5 (EV 43.5b - Net Debt -6.37b = Equity 49.9b / Shares 265.9m; r=9.82% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: 99.37 | Revenue CAGR: 43.20% | SUE: -1.68 | # QB: -3
EPS current Quarter (2026-06-30): EPS=0.38 | Chg30d=+58.85% | Revisions=+25% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-0.20 | Chg30d=-580.58% | Revisions=-25% | Analysts=10
EPS current Year (2026-12-31): EPS=1.01 | Chg30d=+19.99% | Revisions=+60% | GrowthEPS=+159.5% | GrowthRev=+60.2%
EPS next Year (2027-12-31): EPS=1.40 | Chg30d=-3.50% | Revisions=+20% | GrowthEPS=+39.0% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: +60%